Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT05689892

Shared Decision Making in Paediatric Inflammatory Bowel Disease

Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, IBD

Sex: All
Ages: 2 Years – 17 Years
Healthy volunteers: 1
Phase: NA
Enrollment: 150
Sponsor: London Health Sciences Centre

Summary

The goal of this mixed-methods prospective cohort study is to assess the impact of shared decision-making (SDM) on newly diagnosed pediatric inflammatory bowel disease (IBD) patients and their families. Patient and familial decisional conflict regarding the choice and course of treatment is shown to be high, especially for the newer class of IBD treatments called biologic agents. SDM intervention comprises of coaching with a decision coach (DC) on all aspects of treatment and care, along with educational decision aids (DA) provided and adapted from Cincinnati Children's Hospital Medical Center.The main aims of this study are:to determine if SDM intervention has an impact on patient and parental decision making in pediatric IBD treatments, mainly by assessing decisional conflict and decision satisfaction/regret.to adapt and assess the acceptability of DA in a Canadian academic center.Participants who have been recommended a new biologic as part of their clinical care for IBD will be recruited to the SDM intervention group. The participants will have DC sessions until a final treatment decision is made, will be given DAs, and will be followed by baseline and post-intervention surveys to assess decisional conflict and satisfaction/regret.The comparator group will include participants who have been recommended and have commenced a new biologic within the last 12 months.Outcome metrics will evaluate the impact on parental and patient decisional conflict following SDM intervention, and decisional satisfaction/regret 6-12 months from therapy start.

Eligibility Criteria

Inclusion Criteria:English-speaking substitute decision makers and adolescent patients (age 13-17.99 years) with IBD that are recommended a new biologic therapy.English-speaking substitute decision makers and adolescent patients (age 13-17.99 years) with IBD that have started a new biologic therapy within the last 6 to 12 months, without SDM intervention.Exclusion Criteria:patient over age 18non-English speakersacute medical instability or any known major mental illness in parent or adolescent patient

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05689892). StuddyBuddy aggregates publicly available trial information.